Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (26482)	11/14/1998 12:21:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

News Alert from Dow Jones Online News via Quote.com Headline: Ligand Pharmaceuticals' 3rd-Quarter Loss More Than Quadrupled ================================================== Ligand Pharmaceuticals Inc. - San Diego, Calif. 3rd Quar Sept 30: 1998 1997 Revenue $3,947,000 $10,172,000 Inc bef item a (16,275,000) (11,564,000) Extrd item b (30,000,000) .... Net income a (46,275,000) (11,564,000) Avg shrs 40,333,000 32,800,000 Shr earns (basic, diluted) Net income a (1.15) (.35) Figures in parentheses are losses. a. Includes $2 million from realized gain on investments. b. Covers the write-off of in-process technology. Ligand Pharmaceuticals Inc. (LGND) develops small-molecule drugs usedto regulate hormone-activated intracellular receptors. Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.

To: Pseudo Biologist who wrote (26482)	11/14/1998 3:44:00 PM
From: Henry Niman	Respond to of 32384

WSJ Interactive (which includes Dow Jones) only has LGND's press release for 3Q results, and Reuters has the 3Q data under a title something like "3Q Results": biz.yahoo.com At least some quote.com sites just show the LGND press release: fast.quote.com